Toll Free: 1-888-928-9744

Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 183 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H1, 2016" provides an overview of Idiopathic Pulmonary Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials 27 Prominent Drugs 28 Latest Clinical Trials News on Idiopathic Pulmonary Fibrosis 29 May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 29 Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients 30 Mar 22, 2016: Synairgen Announces Positive LOXL2 results 30 Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis 30 Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations 31 Clinical Trial Profile Snapshots 33 Appendix 180 Abbreviations 180 Definitions 180 Research Methodology 181 Secondary Research 181 About GlobalData 182 Contact Us 182 Disclaimer 182 Source 183
List of Tables
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region, 2016* 6 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13 Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2016* 14 Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2016* 17 Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28


List of Figures
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13 Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2016* 14 Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2016* 17 Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28 GlobalData Methodology 181

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify